Quality of life and patient-centered outcomes following atrial fibrillation ablation: Short- and long-term perspectives to improving care

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 7, 2012, Pages 889-900

  Mohanty, Sanghamitra ^a,b   Biase, Luigi Di ^a,c,d   Bai, Rong ^a,e   Santangeli, Pasquale ^a,c   Pump, Agnes ^a,f   Horton, Rodney ^a,d   Sanchez, Javier E ^a   Natale, Andrea ^a,d,g,h  

^a Texas Cardiac Arrhythmia Institute   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF FOGGIA   (Italy)

^d The University of Texas at Austin   (United States)

^e HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^f UNIVERSITY OF PÉCS   (Hungary)

^g STANFORD UNIVERSITY   (United States)

^h SCRIPPS CLINIC   (United States)

Author keywords

ablation outcome; atrial fibrillation; atrial fibrillation genetics; catheter ablation; quality of life; thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; CORTICOSTEROID;

AGE; CARDIAC PATIENT; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; DISEASE DURATION; DISEASE PREDISPOSITION; DRUG WITHDRAWAL; GENDER; GENETIC ASSOCIATION; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INFLAMMATION; METABOLIC SYNDROME X; MORBIDITY; OBESITY; PATIENT CARE; QUALITY OF LIFE; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SHORT FORM 36; SINUS RHYTHM; SOCIAL ASPECT; THROMBOEMBOLISM; TREATMENT OUTCOME;

AGING; ATRIAL FIBRILLATION; CATHETER ABLATION; DISEASE PROGRESSION; HUMANS; INDIVIDUALIZED MEDICINE; METABOLIC SYNDROME X; OBESITY; QUALITY OF LIFE; SEX CHARACTERISTICS; SLEEP APNEA, OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84865448453     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.62     Document Type: Review

References (118)

1. Bhargava M, Di Biase L, Mohanty P et al. Impact of type of atrial fibrillation and repeat catheter ablation on long-term freedom from atrial fibrillation: Results from a multicenter study. Heart Rhythm 6(10), 1403-1412 (2009). Demonstrates that the success rate of catheter ablation increases with repeated procedures.
2. Ip S, Terasawa T, Balk EM, Chung M, Alsheikh-Ali A, Garlitski AC. Comparative Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation. Agency for Healthcare Research and Quality (USA), MD, USA (2009). Report No.: 09-EHC015-EF (2009).
3. Haïssaguerre M, Jaïs P, Shah DC et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N. Engl. J. Med. 339(10), 659-666 (1998). (Pubitemid 28402090)
4. Kazemian P, Oudit G, Jugdutt BI. Atrial fibrillation and heart failure in the elderly. Heart Fail. Rev. 17(4-5), 597-613 (2011).
5. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271(11), 840-844 (1994).
6. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke. 22(8), 983-988 (1991).
7. Pasquale S, Di Biase L, Mohanty P et al. Catheter ablation of atrial fibrillation in octogenarians: Safety and outcomes. J. Cardiovasc. Electrophysiol. doi:10.1111/j.1540-8167.2012.02293.x. (2012) (Epub ahead of print).
8. Haegeli LM, Duru F, Lockwood EE et al. Ablation of atrial fibrillation after the retirement age: Considerations on safety and outcome. J. Interv. Card. Electrophysiol. 28(3), 193-197 (2010).
9. Bunch TJ, Weiss JP, Crandall BG et al. Long-term clinical efficacy and risk of catheter ablation for atrial fibrillation in octogenarians. Pacing Clin. Electrophysiol. 33(2), 146-152 (2010).
10. Tan HW, Wang XH, Shi HF et al. Efficacy, safety and outcome of catheter ablation for atrial fibrillation in octogenarians. Int. J. Cardiol. 145(1), 147-148 (2010).
11. Corrado A, Patel D, Riedlbauchova L et al. Efficacy, safety, and outcome of atrial fibrillation ablation in septuagenarians. J. Cardiovasc. Electrophysiol. 19(8), 807-811 (2008). (Pubitemid 352032783)
12. Michelena HI, Powell BD, Brady PA, Friedman PA, Ezekowitz MD. Gender in atrial fibrillation: Ten years later. Gend. Med. 7(3), 206-217 (2010). Demonstrates how females with atrial fibrillation (AF) are reported to have higher symptom burden, higher stroke risk and higher mortality. Catheter ablation is equally successful in both sexes, but women may incur higher procedural bleeding complications.
13. Watanabe H, Tanabe N, Yagihara N, Watanabe T, Aizawa Y, Kodama M. Association between lipid profile and risk of atrial fibrillation. Circ. J. 75(12), 2767-2774 (2011).
14. Hoyt H, Bhonsale A, Chilukuri K et al. Complications arising from catheter ablation of atrial fibrillation: Temporal trends and predictors. Heart Rhythm 8(12), 1869-1874 (2011).
15. Shah RU, Freeman JV, Shilane D, Wang PJ, Go AS, Hlatky MA. Procedural complications, rehospitalizations, and repeat procedures after catheter ablation for atrial fibrillation. J. Am. Coll. Cardiol. 59(2), 143-149 (2012).
16. Baman TS, Jongnarangsin K, Chugh A et al. Prevalence and predictors of complications of radiofrequency catheter ablation for atrial fibrillation. J. Cardiovasc. Electrophysiol. 22(6), 626-631 (2011).
17. Rostock T, Salukhe TV, Steven D et al. Long-term single- and multiple-procedure outcome and predictors of success after catheter ablation for persistent atrial fibrillation. Heart Rhythm 8(9), 1391-1397 (2011).
18. Patel D, Mohanty P, Di Biase L et al. Outcomes and complications of catheter ablation for atrial fibrillation in females. Heart Rhythm 7(2), 167-172 (2010).
19. Friberg J, Scharling H, Gadsbøll N, Truelsen T, Jensen GB; Copenhagen City Heart Study. Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study). Am. J. Cardiol. 94(7), 889-894 (2004). Demonstrates how AF is a much more pronounced risk factor for stroke and cardiovascular death in women than in men. (Pubitemid 39359174)
20. Potpara TS, Marinkovic JM, Polovina MM et al. Gender-related differences in presentation, treatment and long-term outcome in patients with first-diagnosed atrial fibrillation and structurally normal heart: The Belgrade atrial fibrillation study. Int. J. Cardiol. doi:10.1016/j. ijcard.2011.04.022 (2011) (Epub ahead of print). Gender differences are evident in AF with male patients developing persistent AF more frequently. Male gender is also at higher risk of tachycardiomyopathy, suggesting that these patients require more attention to rate control during follow-up.
21. Mohanty S, Mohanty P, Di Biase L et al. Baseline B-type natriuretic peptide: A gender-specific predictor of procedureoutcome in atrial fibrillation patients undergoing catheter ablation. J. Cardiovasc. Electrophysiol. 22(8), 858-865 (2011).
22. Gudbjartsson DF, Arnar DO, Helgadottir A et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 448(7151), 353-357 (2007). A strong association between two sequence variants on chromosome 4q25 and AF has been detected. Risk of AF increases by 1.72 and 1.39 per copy in individuals of European descent and by 1.42 per copy in the Chinese population. (Pubitemid 47080348)
23. Liu X, Wang F, Knight AC, Zhao J, Xiao J. Common variants for atrial fibrillation: Results from genome-wide association studies. Hum. Genet. 131(1), 33-39 (2011).
24. Viviani Anselmi C, Novelli V, Roncarati R et al. Association of rs2200733 at 4q25 with atrial flutter/fibrillation diseases in an Italian population. Heart 94(11), 1394-1396 (2008).
25. Kääb S, Darbar D, van Noord C et al. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur. Heart J. 30(7), 813-819 (2009).
26. Lubitz SA, Sinner MF, Lunetta KL et al. Independent susceptibility markers for atrial fibrillation on chromosome 4q25. Circulation 122(10), 976-984 (2010).
27. Gretarsdottir S, Baas AF, Thorleifsson G et al. Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm. Nat. Genet. 42(8), 692-697 (2010).
28. Husser D, Adams V, Piorkowski C, Hindricks G, Bollmann A. Chromosome 4q25 variants and atrial fibrillation recurrence after catheter ablation. J. Am. Coll. Cardiol. 55(8), 747-753 (2010). The noncoding variants on chromosome 4q25, rs2200733 and rs10033464, modulate the risk for AF recurrence after catheter ablation.
29. Wang TJ, Parise H, Levy D et al. Obesity and the risk of new-onset atrial fibrillation. JAMA 292(20), 2471-2477 (2004). (Pubitemid 39552671)
30. Tedrow UB, Conen D, Ridker PM et al. The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (Women's Health Study). J. Am. Coll. Cardiol. 55(21), 2319-2327 (2010).
31. Ardestani A, Hoffman HJ, Cooper HA. Obesity and outcomes among patients with established atrial fibrillation. Am. J. Cardiol. 106(3), 369-373 (2010).
32. Mohanty S, Mohanty P, Di Biase L et al. Influence of body mass index on quality of life in atrial fibrillation patients undergoing catheter ablation. Heart Rhythm 8(12), 1847-1852 (2011).
33. Nguyen JT, Benditt DG. Atrial fibrillation susceptibility in metabolic syndrome: Simply the sum of its parts? Circulation 117(10), 1249-1251 (2008). (Pubitemid 351372068)
34. Watanabe H, Tanabe N, Watanabe T et al. Metabolic syndrome and risk of development of atrial fibrillation: The Niigata preventive medicine study. Circulation 117(10), 1255-1260 (2008). (Pubitemid 351365676)
35. Chamberlain AM, Agarwal SK, Ambrose M, Folsom AR, Soliman EZ, Alonso A. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am. Heart J. 159(5), 850-856 (2010).
36. Cai L, Yin Y, Ling Z et al. Predictors of late recurrence of atrial fibrillation after catheter ablation. Int. J. Cardiol. 10(3), 221-226 (2011).
37. Chang SL, Tuan TC, Tai CT et al. Comparison of outcome in catheter ablation of atrial fibrillation in patients with versus without the metabolic syndrome. Am. J. Cardiol. 103(1), 67-72 (2009). MS is associated with higher incidence of non-PV triggers, larger left atrial size and an arrhythmogenic substrate, which may increase the risk for recurrence after the ablation of AF.
38. Ri-Bo T, Jian-Zeng D, Xing-Peng L et al. Metabolic syndrome and risk of recurrence of atrial fibrillation after catheter ablation. Circ. J. 73,438-443 (2009).
39. Letsas KP, Weber R, Bürkle G et al. Pre-ablative predictors of atrial fibrillation recurrence following pulmonary vein isolation: The potential role of inflammation. Europace 11(2), 158-163 (2009).
40. Mohanty S, Mohanty P, Di Biase L et al. Impact of metabolic syndrome on procedural outcomes in patients with atrial fibrillation undergoing catheter ablation. J. Am. Coll. Cardiol. 59(14), 1295-1301 (2012). Baseline inflammatory markers and presence of MS predict higher recurrence after single catheter ablation in non-paroxysmal AF.
41. Kipshidze NN, Katsitadze GA, Khosroshvili LB. [Effect of the metabolic syndrome on the electrophysiological parameters of the heart]. Georgian Med. News 119, 9-13 (2005).
42. Oliveira MM, da Silva N, Timóteo AT et al. Enhanced dispersion of atrial refractoriness as an electrophysiological substrate for vulnerability to atrial fibrillation in patients with paroxysmal atrial fibrillation. Rev. Port. Cardiol. 26(7-8), 691-702 (2007). (Pubitemid 47477434)
43. Chilukuri K, Dalal D, Marine JE et al. Predictive value of obstructive sleep apnoea assessed by the Berlin Questionnaire for outcomes after the catheter ablation of atrial fibrillation. Europace 11(7), 896-901 (2009).
44. Tang RB, Dong JZ, Liu XP et al. Obstructive sleep apnoea risk profile and the risk of recurrence of atrial fibrillation after catheter ablation. Europace 11(1), 100-105 (2009).
45. Matiello M, Nadal M, Tamborero D et al. Low efficacy of atrial fibrillation ablation in severe obstructive sleep apnoea patients. Europace 12(8), 1084-1089 (2010).
46. Hoyer FF, Lickfett LM, Mittmann-Braun E et al. High prevalence of obstructive sleep apnea in patients with resistant paroxysmal atrial fibrillation after pulmonary vein isolation. J. Interv. Card. Electrophysiol. 29(1), 37-41 (2010).
47. Patel D, Mohanty P, Di Biase L et al. Safety and efficacy of pulmonary vein antral isolation in patients with obstructive sleep apnea: The impact of continuous positive airway pressure. Circ. Arrhythm. Electrophysiol. 3(5), 445-451 (2010).
48. Camm JA, Kirchhof P, Lip GYH et al. Guidelines for the management of atrial fibrillation. Eur. Heart J. 31, 2369-2429 (2010).
49. Nilsson B, Chen X, Pehrson S, Køber L, Hilden J, Svendsen JH. Recurrence of pulmonary vein conduction and atrial fibrillation after pulmonary vein isolation for atrial fibrillation: A randomized trial of the ostial versus the extraostial ablation strategy. Am. Heart J. 152(3), 537.e1-537.e8 (2006).
50. Berruezo A, Tamborero D, Mont L et al. Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur. Heart J. 28(7), 836-841 (2007). (Pubitemid 47343599)
51. Zhuang J, Wang Y, Tang K et al. Association between left atrial size and atrial fibrillation recurrence after single circumferential pulmonary vein isolation: A systematic review and meta-analysis of observational studies. Europace 14(5), 638-645 (2011).
52. Jaïs P, Cauchemez B, Macle L et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: The A4 study. Circulation 118(24), 2498-2505 (2008).
53. Cha YM, Friedman PA, Asirvatham SJ et al. Catheter ablation for atrial fibrillation in patients with obesity. Circulation 117(20), 2583-2590 (2008).
54. Al Chekakie MO, Akar JG, Wang F et al. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation. J. Cardiovasc. Electrophysiol. 18(9), 942-946 (2007). (Pubitemid 47339045)
55. Calò L, Lamberti F, Loricchio ML et al. Left atrial ablation versus biatrial ablation for persistent and permanent atrial fibrillation: A prospective and randomized study. J. Am. Coll. Cardiol. 47(12), 2504-2512 (2006). (Pubitemid 43866384)
56. Chen MS, Marrouche NF, Khaykin Y et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J. Am. Coll. Cardiol. 43(6), 1004-1009 (2004). (Pubitemid 38352980)
57. Hsu LF, Jaïs P, Sanders P et al. Catheter ablation for atrial fibrillation in congestive heart failure. N. Engl. J. Med. 351(23), 2373-2383 (2004).
58. Wilton SB, Fundytus A, Ghali WA et al. Meta-analysis of the effectiveness and safety of catheter ablation of atrial fibrillation in patients with versus without left ventricular systolic dysfunction. Am. J. Cardiol. 106(9), 1284-1291 (2010).
59. Themistoclakis S, Schweikert RA, Saliba WI et al. Clinical predictors and relationship between early and late atrial tachyarrhythmias after pulmonary vein antrum isolation. Heart Rhythm 5(5), 679-685 (2008).
60. Della Bella P, Riva S, Fassini G et al. Long-term follow-up after radiofrequency catheter ablation of atrial fibrillation: Role of the acute procedure outcome and of the clinical presentation. Europace 7(2), 95-103 (2005). (Pubitemid 40347852)
61. Fiala M, Chovancík J, Nevralová R et al. Termination of long-lasting persistent versus short-lasting persistent and paroxysmal atrial fibrillation by ablation. Pacing Clin. Electrophysiol. 31(8), 985-997 (2008).
62. Tao H, Liu X, Dong J et al. Predictors of very late recurrence of atrial fibrillation after circumferential pulmonary vein ablation. Clin. Cardiol. 31(10), 463-468 (2008).
63. Potpara T, Grujic M, Vujisic-Tesic B et al. [Relationship between the type of atrial fibrillation and thromboembolic events]. Vojnosanit. Pregl. 66(11), 887-891 (2009).
64. Hohnloser SH, Pajitnev D, Pogue J et al.; ACTIVE W Investigators. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: An ACTIVE W Substudy. J. Am. Coll. Cardiol. 50(22), 2156-2161 (2007). (Pubitemid 350123679)
65. Zhou JM, Liu SW, Lin JX et al. Thromboembolic event rate in patients with persistent or paroxysmal atrial fibrillation post circumferential pulmonary vein isolation: A single center experience in China. Chin. Med. J. 120(11), 956-959 (2007).
66. Verma A, Wazni OM, Marrouche NF et al. Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: An independent predictor of procedural failure. J. Am. Coll. Cardiol. 45(2), 285-292 (2005). (Pubitemid 40094739)
67. Uijl D, Delgado V, Bertini M et al. Impact of left atrial fibrosis and left atrial size on the outcome of catheter ablation for atrial fibrillation. Heart 97, 1847e-1851e (2011).
68. Okumura Y, Watanabe I, Nakai T et al. Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: Importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence. J. Cardiovasc. Electrophysiol. 22(9), 987-993 (2011).
69. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: A systematic review of the published data. J. Am. Coll. Cardiol. 50(21), 2021-2028 (2007). (Pubitemid 350087568)
70. Friedrichs K, Klinke A, Baldus S. Inflammatory pathways underlying atrial fibrillation. Trends Mol. Med. 17(10), 556-563 (2011).
71. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: Review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: Secondary prevention. Europace 13(5), 610-625 (2011). Secondary prevention of AF may become possible by retarding the process of atrial remodeling with upstream therapies including angiotensin-converting enzyme inhibitors (ACEIs), angiotensin-receptor blockers (ARBs), aldosterone antagonists, statins, and ω-3 fatty acid.
72. Rahimi K, Emberson J, McGale P et al.; PROSPER Executive. Effect of statins on atrial fibrillation: Collaborative metaanalysis of published and unpublished evidence from randomised controlled trials. BMJ 342, d1250 (2011).
73. Ozaydin M. Atrial fibrillation and inflammation. World J. Cardiol. 2(8), 243-250 (2010).
74. Dienera HC, Webera R, Lip G, Hohnloser SH. Stroke prevention in atrial fibrillation: Do we still need warfarin? Curr. Opin. Neurol. 25, 27-35 (2012).
75. Calkins H, Brugada J, Packer DL et al.; European Heart Rhythm Association (EHRA) European Cardiac Arrhythmia Scoiety (ECAS) American College of Cardiology (ACC) American Heart Association (AHA) Society of Thoracic Surgeons (STS). HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: Recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 4(6), 816-861 (2007).
76. Yagishita A, Takahashi Y, Takahashi A et al. Incidence of late thromboembolic events after catheter ablation of atrial fibrillation. Circ. J. 75(10), 2343-2349 (2011).
77. Saad EB, d'Avila A, Costa IP et al. Very low risk of thromboembolic events in patients undergoing successful catheter ablation of atrial fibrillation with a CHADS2 score =3: A long-term outcome study. Circ. Arrhythm. Electrophysiol. 4(5), 615-621 (2011).
78. Themistoclakis S, Corrado A, Marchlinski FE et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. J. Am. Coll. Cardiol. 55(8), 735-743 (2010).
79. Koichiro K. Catheter ablation of atrial fibrillation - state of the art. Circ. J. 75, 2305-2311 (2011).
80. Santangeli P, Di Biase L, Pelargonio G et al. Catheter ablation of atrial fibrillation: Randomized controlled trials and registries, a look back and the view forward. J. Interv. Card. Electrophysiol. 31(1), 69-80 (2011).
81. Di Biase L, Burkhardt JD, Mohanty P et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: The impact of periprocedural therapeutic international normalized ratio. Circulation 121(23), 2550-2556 (2010).
82. Marchlinski FE, Callans D, Dixit S et al. Efficacy and safety of targeted focal ablation versus PV isolation assisted by magnetic electroanatomic mapping. J. Cardiovasc. Electrophysiol. 14(4), 358-365 (2003). (Pubitemid 36529019)
83. Arruda M, Mlcochova H, Prasad SK et al. Electrical isolation of the superior vena cava: An adjunctive strategy to pulmonary vein antrum isolation improving the outcome of AF ablation. J. Cardiovasc. Electrophysiol. 18(12), 1261-1266 (2007). (Pubitemid 350115776)
84. Corrado A, Bonso A, Madalosso M et al. Impact of systematic isolation of superior vena cava in addition to pulmonary vein antrum isolation on the outcome of paroxysmal, persistent, and permanent atrial fibrillation ablation: Results from a randomized study. J. Cardiovasc. Electrophysiol. 21(1), 1-5 (2010).
85. Miyazaki S, Kuwahara T, Kobori A et al. Long-term clinical outcome of extensive pulmonary vein isolation-based catheter ablation therapy in patients with paroxysmal and persistent atrial fibrillation. Heart 97(8), 668-673 (2011).
86. Takahashi Y, Sanders P, Rotter M, Haïssaguerre M. Disconnection of the left atrial appendage for elimination of foci maintaining atrial fibrillation. J. Cardiovasc. Electrophysiol. 16(8), 917-919 (2005). (Pubitemid 41623786)
87. Di Biase L, Burkhardt JD, Mohanty P et al. Left atrial appendage: An underrecognized trigger site of atrial fibrillation. Circulation 122(2), 109-118 (2010). Points out the relevance of the left atrial appendage (LAA) as a non-PV trigger site for AF and the importance of the LAA isolation to improve long-term outcomes.
88. Kurotobi T, Ito H, Inoue K et al. Marshall vein as arrhythmogenic source in patients with atrial fibrillation: Correlation between its anatomy and electrophysiological findings. J. Cardiovasc. Electrophysiol. 17(10), 1062-1067 (2006). (Pubitemid 44401563)
89. Lin WS, Tai CT, Hsieh MH et al. Catheter ablation of paroxysmal atrial fibrillation initiated by non-pulmonary vein ectopy. Circulation 107(25), 3176-3183 (2003).
90. Hsu LF, Jaïs P, Keane D et al. Atrial fibrillation originating from persistent left superior vena cava. Circulation 109(7), 828-832 (2004). (Pubitemid 38252732)
91. Elayi CS, DI Biase L, Bai R et al. Identifying the relationship between the non-PV triggers and the critical CFAE sites post-PVAI to curtail the extent of atrial ablation in longstanding persistent AF. J. Cardiovasc. Electrophysiol. 22(11), 1199-1205 (2011). CFAE ablation after PVAI was associated with a significantly higher elimination of non-PV triggers.
92. Fisher JD, Spinelli MA, Mookherjee D, Krumerman AK, Palma EC. Atrial fibrillation ablation: Reaching the mainstream. Pacing Clin. Electrophysiol. 29(5), 523-537 (2006).
93. Piorkowski C, Kottkamp H, Tanner H et al. Value of different follow-up strategies to assess the efficacy of circumferential pulmonary vein ablation for the curative treatment of atrial fibrillation. J. Cardiovasc. Electrophysiol. 16(12), 1286-1292 (2005).
94. Vasamreddy CR, Dalal D, Dong J et al. Symptomatic and asymptomatic atrial fibrillation in patients undergoing radiofrequency catheter ablation. J. Cardiovasc. Electrophysiol. 17(2), 134-139 (2006). (Pubitemid 43344863)
95. Kottkamp H, Tanner H, Kobza R et al. Time courses and quantitative analysis of atrial fibrillation episode number and duration after circular plus linear left atrial lesions: Trigger elimination or substrate modification: Early or delayed cure? J. Am. Coll. Cardiol. 44(4), 869-877 (2004). (Pubitemid 39099587)
96. Mulder AA, Wijffels MC, Wever EF, Kelder JC, Boersma LV. Arrhythmia detection after atrial fibrillation ablation: Value of incremental monitoring time. Pacing Clin. Electrophysiol. 35(2), 164-169 (2012).
97. Verma A, Champagne J, Sapp J et al. Discerning the incidence of symptomatic and asymptomatic episodes of atrial fibrillation pre- and post-radiofrequency ablation (DISCERN AF): A prospective, multicenter study. Presented at: The Heart Rhythm Society 2011 Scientific Sessions. San Francisco, CA, USA, 5 May 2011 (Abstract LB-02).
98. Reynolds MR, Ellis E, Zimetbaum P. Quality of life in atrial fibrillation: Measurement tools and impact of interventions. J. Cardiovasc. Electrophysiol. 19(7), 762-768 (2008).
99. Reynolds MR, Tara Lavelle T, Essebag V, Cohen DJ, Zimetbaum P. Influence of age, gender, and AF recurrence on quality of life outcomes in a population of new-onset AF patients: The FRACTAL Registry. Am. Heart J. 152(6), 1097-1103 (2006).
100. Ong L, Irvine J, Nolan R et al. Gender differences and quality of life in atrial fibrillation: The mediating role of depression. J. Psychosom. Res. 61(6), 769-774 (2006). (Pubitemid 44830039)
101. Dagres N, Nieuwlaat R, Vardas PE et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: A report from the Euro Heart Survey on Atrial Fibrillation. J. Am. Coll. Cardiol. 49(5), 572-577 (2007). (Pubitemid 46177436)
102. Paquette M, Roy D, Talajic M et al. Role of gender and personality on quality-of-life impairment in intermittent atrial fibrillation. Am. J. Cardiol. 86(7), 764-768 (2000).
103. Howes CJ, Reid MC, Brandt C et al. Exercise tolerance and quality of life in elderly patients with chronic atrial fibrillation. J. Cardiovasc. Pharmacol. Ther. 6(1), 23-29 (2001). (Pubitemid 32979884)
104. Rådholm K, Östgren CJ, Alehagen U et al. Atrial fibrillation (AF) and co-morbidity in elderly. A population based survey of 85 years old subjects. Arch. Gerontol. Geriatr. 52(3), e170-e175 (2011).
105. Weerasooriya R, Jaïs P, Hocini M et al. Effect of catheter ablation on quality of life of patients with paroxysmal atrial fibrillation. Heart Rhythm 2(6), 619-623 (2005). (Pubitemid 40724129)
106. Fichtner S, Deisenhofer I, Kindsmüller S et al. Prospective assessment of short- and long-term quality of life after ablation for atrial fibrillation. J. Cardiovasc. Electrophysiol. 23(2), 121-127 (2012). Quality of life improves irrespective of AF type following catheter ablation; being significantly better in patients who undergo a successful ablation than those with unsuccessful procedure.
107. Goldberg A, Menen M, Mickelsen S et al. Atrial fibrillation ablation leads to long-term improvement of quality of life and reduced utilization of healthcare resources. J. Interv. Card. Electrophysiol. 8(1), 59-64 (2003). Ablation of focal triggers of atrial fibrillation is associated with a sustained improvement in quality of life. Although the initial cost of ablation is high, after ablation, utilization of healthcare resources is significantly reduced. (Pubitemid 36356174)
108. Peinado R, Arribas F, Ormaetxe JM, Badía X. Variation in quality of life with type of atrial fibrillation. Rev. Esp. Cardiol. 63(12), 1402-1409 (2010).
109. Wokhlu A, Monahan KH, Hodge DO et al. Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. J. Am. Coll. Cardiol. 55(21), 2308-2316 (2010). AF ablation produces sustained QoL improvement at 2 years follow-up, in patients with and without recurrence.
110. Spertus J, Dorian P, Bubien R et al. Development and validation of the atrial fibrillation effect on quality-of-life (AFEQT) questionnaire in patients with atrial fibrillation. Circ. Arrhythm. Electrophysiol. 4(1), 15-25 (2011).
111. Arribas F, Ormaetxe JM, Peinado R, Perulero N, Ramírez P, Badia X. Validation of the AF-QoL, a diseasespecific quality of life questionnaire for patients with atrial fibrillation. Europace 12(3), 364-370 (2010).
112. Thrall G, Lip GY, Carroll D, Lane D. Depression, anxiety, and quality of life in patients with atrial fibrillation. Chest 132(4), 1259-1264 (2007). (Pubitemid 47621002)
113. Lange HW, Herrmann-Lingen C. Depressive symptoms predict recurrence of atrial fibrillation after cardioversion. J. Psychosom. Res. 63(5), 509-513 (2007). (Pubitemid 350007666)
114. Andrade JG, Khairy P, Verma A et al. Early recurrence of atrial tachyarrhythmias following radiofrequency catheter ablation of atrial fibrillation. Pacing Clin. Electrophysiol. 35(1), 106-116 (2012).
115. Jahangir A, Lee V, Friedman PA et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: A 30-year follow-up study. Circulation 115(24), 3050-3056 (2007). (Pubitemid 46956493)
116. Pappone C, Radinovic A, Manguso F et al. Atrial fibrillation progression and management: A 5-year prospective follow-up study. Heart Rhythm 5(11), 1501-1507 (2008).
117. Pappone C, Vicedomini G, Augello G et al. Radiofrequency catheter ablation and antiarrhythmic drug therapy: A prospective, randomized, 4-year follow-up trial: The APAF study. Circ. Arrhythm. Electrophysiol. 4(6), 808-814 (2011).
118. Daly M, Melton I, Crozier I. Pulmonary vein ablation for atrial fibrillation: The Christchurch, New Zealand experience. J. NZ Med. Assoc. 124, 1343 (2011).